参考文献/References:
1 Valk PE,Pounds TR,Tesar RD,et al.Cost-effectiveness of PET imaging in clinical oncology.Nucl Med Biol,1996,23(6):737-743.
2 Gambhir SS,Shepherd JE,Shah BD,et al.Analytical decision model for the cost-effective management of solitary pulmonary nodules.J Clin Oncol,1998,16(6):2113-2125.
3 Miles KA.An approach to demonstrating cost-effectiveness of diagnostic imaging modalities in Australia illustrated by PET.Austr Radiol,2001,45(1):9-18.
4 Keith CJ,Miles KA,Griffiths MR,et al.Solitary pulmonary nodules:accuracy and cost-effectiveness of sodium iodide FDG-PET using Australian data.Eur J Nucl Med Mol Imaging,2002,29(8):1016-1023.
5 Kosuda S,Ichihara K,Watanabe M,et al.Decision-tree sensitivity analysis for cost-effectiveness of FDG-PET in patients with pulmonary nodules(non-small cell lung carcinoma) in Japan.Chest,2000,117(2):346-353.
6 Dietlein M,Weber K,Gandiour A,et al.Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules:a decision analysis based on cost reimbursement in Germany.Eur J Nucl Med,2000,27(10):1441-1456.
7 Gugiatti A,Grimaldi A,Rossetti C,et al.Economic analyses on the use of positron emission tomography for the work-up of solitary pulmonary nodules and for staging patients with non-small-celllung-cancer in Italy.Q J Nucl Med,2004,48(1):49-61.
8 Gambhir SS,Hoh CK,Phelps ME,et al.Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.J Nucl Med,1996,37(9):1428-1436.
9 Scott WJ,Shelpherd J,Gambhir SS.Cost-effectiveness of FDG-PET for staging non-small-cell lung carcinoma:a decision analysis.Ann Thorac Surg,1998,66(6):1876-1883.
10 Yap KK,Yap KS,Byrne AJ,et al.Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.Eur J Nucl Med Mol Imaging,2005,32(9):1033-1040.
11 Alzahouri K,Lejeune C,Woronoff-Lemsi MC,et al.Cost-effectiveness analysis of strategies introducing FDG-PET into the mediastinal staging of non-small-cell lung cancer from the French healthcare system perspective.Clin Radiol,2005,60(4):479-492.
12 Sloka JS,Hollett PD,Mathews M.Cost-effectiveness of positron emission tomography for non-small cell lung carcinoma in Canada.Med Sci Monit,2004,10(5):MT73-MT80.
13 Nguyen VH,Peloquin S,Lacasse Y.Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec.Can Respir J,2005,12(1):19-25.
14 Kosuda S,Ichihara K,Watanabe M,et al.Decision-tree sensitivity analysis for cost-effectiveness of whole-body FDG PET in the management of patients with non-small cell lung carcinoma in Japan.Ann Nucl Med,2002,16(4):263-271.
15 Dietlein M,Weber K,Gandiour A,et al.Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer:priority for a PET-based strategy after nodal-negative CT results.Eur J Nucl Med,2000,27(11):1598-1609.
16 Zubeldia JM,Bednarczyk EM,Baker JG,et al.The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases.Cancer Biother Radiopharm,2005,20(4):450-456.
17 Sloka JS,Hollett PD.Cost effectiveness of positron emission tomography in Canada.Med Sci Monit,2005,11(10):PH1-PH6.
18 Hollenbeak CS,Lowe VJ,Stack BC Jr.The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the NO neck.Cancer,2001,92(9):2341-2348
19 Bongers V,Hobbelink MG,van Rijk PP,et al.Cost-effectiveness ofdual-head 18F-fluorodeoxyglucose PET for the detection of recurrent laryngeal cancer.Cancer Biother Radiopharm,2002,17(3):303-306.
20 Hoh CK,Glaspy J,Rosen P,et al.Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma.J Nucl Med,1997,38(3):343-348.
21 Klose T,Leidl R,Buchmann I,et al.Primary staging of lymphomas:cost-effectiveness of FDG-PET versus computed tomography.Eur J Nucl Med,2000,27(10):1457-1464.
22 Sloka JS,Hollett PD,Mathews M.Cost-effectiveness of positron emission tomography in breast cancer.Mol Imaging Biol,2005,7(5):351-360.
23 Tsushima Y,Endo K.Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules.Med Sci Monit,2004,10(5):MT65-MT72.
相似文献/References:
[1]周玉祥,蓝博文,黄春榆,等.64排螺旋CT冠状动脉血管成像诊断冠状动脉-肺动脉瘘的应用价值[J].国际放射医学核医学杂志,2016,40(1):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
Zhou Yuxiang,Lan Bowen,Huang Chunyu,et al.Clinical value of coronary artery-pulmonary artery fistula revealed by 64-slice spiral CT coronary angiography[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):26.[doi:10.3760/cma.j.issn.1673-4114.2016.01.006]
[2]陈超坤,刘亮,傅飞先,等.囊性胸腺瘤和囊性畸胎瘤的影像学特征及鉴别诊断[J].国际放射医学核医学杂志,2016,40(1):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
Chen Chaokun,Liu Liang,Fu Feixian,et al.Imaging features and differential diagnosis of cystic thymoma and cystic teratoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):31.[doi:10.3760/cma.j.issn.1673-4114.2016.01.007]
[3]岳进,苏丽萍.全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用[J].国际放射医学核医学杂志,2016,40(1):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
Yue Jin,Su Lipin.Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):50.[doi:10.3760/cma.j.issn.1673-4114.2016.01.010]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]麦卫平,张永林.能谱CT成像在肺癌诊断中的应用研究进展[J].国际放射医学核医学杂志,2016,40(1):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
Mai Weiping,Zhang Yonglin.Research progress of spectral imaging in the diagnosis of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):77.[doi:10.3760/cma.j.issn.1673-4114.2016.01.015]
[6]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[7]周翠屏,廖俊杰,何国华,等.原发性肠系膜巨大淋巴结增生症的MSCT表现与病理对照分析[J].国际放射医学核医学杂志,2016,40(3):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
Zhou Cuiping,Liao Junjie,He Guohua,et al.Primary mesenteric Castleman disease:MSCT findings with histopathologic correlation[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):175.[doi:10.3760/cma.j.issn.1673-4114.2016.03.003]
[8]张巧娜,刘汉东.上颌窦上皮-肌上皮癌的CT表现一例[J].国际放射医学核医学杂志,2016,40(3):237.[doi:10.3760/cma.j.issn.1673-4114.2016.03.015]
[9]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[10]王朋,崔邦平,代文莉,等.18F-FDG PET/CT在前列腺癌中的应用进展[J].国际放射医学核医学杂志,2016,40(4):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]
Wang Peng,Cui Bangping,Dai Wenli,et al.Progress in the application of 18F-FDG PET/CT in prostate cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):277.[doi:10.3760/cma.j.issn.1673-4114.2016.04.008]